This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Tepperman submitted an expert report on behalf of Respondent in LCIA proceeding involving damages resulting from allegedly delayed delivery of active pharmaceutical ingredient to manufacturer.
He quantified lost tablet sales in Canada under the assumption of delayed supply, including potential for future harm in the form of lost market share (i.e., lost “first-mover advantage”), and critiqued the opposing expert analysis.
Dear Clients and Friends, Our activities in 2024 reflected ongoing trends from 2023 and emerging forces affecting the landscape for investors and companies...
2023 marked a significant surge in activity across diverse sectors such as mining, oil & gas, the energy transition, pharma, and merger disputes. Throughout...
